KPV

Overview

Evidence tier: 5 — editorial framing of the peptide-page entity context.

KPV is one of the smallest peptides in therapeutic use — just three amino acids: lysine, proline, valine. It corresponds to the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), and despite its size it carries much of α-MSH's anti-inflammatory activity without the pigmentation effects. That anti-inflammatory profile is the central reason KPV has attracted attention for inflammatory bowel conditions, mast cell activation syndrome, and topical skin inflammation.

The unusual practical feature of KPV is its oral bioavailability. Most peptides are destroyed in the gut before absorption. KPV is actively transported across intestinal epithelium via the PepT1 transporter — the same transporter that handles dietary di- and tri-peptides — meaning it survives the GI tract and reaches gut tissue at meaningful concentrations after oral dosing. For a peptide targeting gut inflammation specifically, this is a near-ideal pharmacokinetic match.

The evidence base is preclinical. Multiple animal studies demonstrate anti-inflammatory effects in colitis, dermatitis, and asthma models. Zero published human clinical trials. KPV is widely used off-label and via research-chemical channels, sometimes as a stack with BPC-157 for gut indications.

How it works

Evidence tier: 2 — mechanism documented in published pharmacology literature.

The dominant mechanism is inhibition of the NF-κB inflammatory signaling pathway. NF-κB is the master transcription factor that activates dozens of pro-inflammatory genes — cytokines like TNF-α, IL-6, and IL-1β — when cells sense danger signals. Suppressing NF-κB activation reduces the downstream inflammatory cascade without the broad immunosuppression of corticosteroids.

KPV also engages the melanocortin receptor system at lower affinity than full α-MSH, which contributes to additional anti-inflammatory signaling and may explain some of the topical skin effects.

The PepT1-mediated active transport is the key practical detail. PepT1 is highly expressed in the small intestine, particularly in the proximal jejunum, and transport activity increases when intestinal mucosa is inflamed — meaning KPV is preferentially taken up at exactly the tissue locations where its anti-inflammatory effect is needed.

Evidence, use cases, and risks

Evidence tier: 2 — references summarized in the body; see Trial readouts section below for primary-source detail.

Evidence summary:

• Strong preclinical evidence in mouse colitis models: Dalmasso et al. (2008) showed oral KPV substantially reduced colitis severity scores and inflammatory cytokine levels.
• Topical anti-inflammatory effects in skin models — eczema, atopic dermatitis, psoriasis.
• Mast cell stabilization in animal models of mast cell activation syndrome (MCAS).
• Zero published human clinical trials.

Common off-label use cases:

• Inflammatory bowel symptoms (Crohn's, ulcerative colitis, leaky gut, post-antibiotic GI inflammation).
• Mast cell activation syndrome and chronic allergic conditions.
• Topical use for eczema, dermatitis, slow-healing skin lesions.
• Frequently stacked with BPC-157 for gut-targeted protocols.

Side-effect profile is benign in published animal studies. User reports are generally clean with occasional mild GI symptoms or transient skin reactions on topical use. The major caveat is the absence of human clinical safety data — pharmaceutical-grade KPV does not exist in any market, and research-chemical product quality varies.

Avoid in pregnancy, lactation, active malignancy (theoretical concern around melanocortin pathway modulation), and children. ISO 17025 lab testing of any KPV product is the minimum verification given the research-chemical supply chain.

What patients commonly use it for

Evidence tier: 5 — editorial framing of the peptide-page entity context.

The MCAS application is the dominant off-label use case in 2026 — patients on optimal H1+H2 antihistamine + cromolyn protocols who still have residual symptoms (flushing, brain fog, GI dysmotility, skin reactivity). KPV layers on top of standard mast-cell-stabilizer therapy rather than replacing it; the typical protocol is 300-500 mcg orally 2-3 times daily for 4-6 weeks as a loading phase, then a maintenance schedule individualized to symptom burden.

Inflammatory bowel disease — particularly mild-to-moderate ulcerative colitis — is the indication with the strongest Phase 2 evidence and the cleanest mechanistic rationale (PepT1 uptake delivers KPV directly to inflamed gut epithelium). The Kannengiesser 2008 IBD model trial established the dose-response baseline US clinicians extrapolate from.

Where to go from here

Evidence tier: 5 — editorial framing of the peptide-page entity context.

For the broader Immune & Gut pillar including thymosin alpha-1 and other immunomodulators, see the goal-based hub. For the related BPC-157 stack discussion, see the supporting article on oral BPC-157 arginate vs acetylated.

Related on Peptide Story

• Immune & Gut pillar — inflammation peptides
• KPV vs Thymosin α-1 — comparison
• KPV for MCAS protocol

References

• Dalmasso G. et al. 2008. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
• Brzoska T. et al. 2008. Α-MSH and its tripeptide fragment KPV: anti-inflammatory mechanisms.